Central administration of C-X-C chemokine receptor type 4 antagonist alleviates the development and maintenance of peripheral neuropathic pain in mice.

<h4>Aim</h4>To explore the roles of C-X-C chemokine receptor type 4 (CXCR4) in spinal processing of neuropathic pain at the central nervous system (CNS).<h4>Methods</h4>Peripheral neuropathic pain (PNP) induced by partial sciatic nerve ligation (pSNL) model was assessed in mi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xin Luo, Wai Lydia Tai, Liting Sun, Qiu Qiu, Zhengyuan Xia, Sookja Kim Chung, Chi Wai Cheung
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/baece4fdcba340a095d59d3f96ca0ab4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:baece4fdcba340a095d59d3f96ca0ab4
record_format	dspace
spelling	oai:doaj.org-article:baece4fdcba340a095d59d3f96ca0ab42021-11-25T06:04:54ZCentral administration of C-X-C chemokine receptor type 4 antagonist alleviates the development and maintenance of peripheral neuropathic pain in mice.1932-620310.1371/journal.pone.0104860https://doaj.org/article/baece4fdcba340a095d59d3f96ca0ab42014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25119456/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Aim</h4>To explore the roles of C-X-C chemokine receptor type 4 (CXCR4) in spinal processing of neuropathic pain at the central nervous system (CNS).<h4>Methods</h4>Peripheral neuropathic pain (PNP) induced by partial sciatic nerve ligation (pSNL) model was assessed in mice. Effects of a single intrathecal (central) administration of AMD3100 (intrathecal AMD3100), a CXCR4 antagonist, on pain behavior and pain-related spinal pathways and molecules in the L3-L5 spinal cord segment was studied compare to saline treatment.<h4>Results</h4>Rotarod test showed that intrathecal AMD3100 did not impair mice motor function. In pSNL-induced mice, intrathecal AMD3100 delayed the development of mechanical allodynia and reversed the established mechanical allodynia in a dose-dependent way. Moreover, intrathecal AMD3100 downregulated the activation of JNK1 and p38 pathways and the protein expression of p65 as assessed by western blotting. Real-time PCR test also demonstrated that substance P mRNA was decreased, while adrenomedullin and intercellular adhesion molecule mRNA was increased following AMD3100 treatment.<h4>Conclusion</h4>Our results suggest that central (spinal) CXCR4 is involved in the development and maintenance of PNP and the regulation of multiple spinal molecular events under pain condition, implicating that CXCR4 would potentially be a therapeutic target for chronic neuropathic pain.Xin LuoWai Lydia TaiLiting SunQiu QiuZhengyuan XiaSookja Kim ChungChi Wai CheungPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 8, p e104860 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Xin Luo Wai Lydia Tai Liting Sun Qiu Qiu Zhengyuan Xia Sookja Kim Chung Chi Wai Cheung Central administration of C-X-C chemokine receptor type 4 antagonist alleviates the development and maintenance of peripheral neuropathic pain in mice.
description	<h4>Aim</h4>To explore the roles of C-X-C chemokine receptor type 4 (CXCR4) in spinal processing of neuropathic pain at the central nervous system (CNS).<h4>Methods</h4>Peripheral neuropathic pain (PNP) induced by partial sciatic nerve ligation (pSNL) model was assessed in mice. Effects of a single intrathecal (central) administration of AMD3100 (intrathecal AMD3100), a CXCR4 antagonist, on pain behavior and pain-related spinal pathways and molecules in the L3-L5 spinal cord segment was studied compare to saline treatment.<h4>Results</h4>Rotarod test showed that intrathecal AMD3100 did not impair mice motor function. In pSNL-induced mice, intrathecal AMD3100 delayed the development of mechanical allodynia and reversed the established mechanical allodynia in a dose-dependent way. Moreover, intrathecal AMD3100 downregulated the activation of JNK1 and p38 pathways and the protein expression of p65 as assessed by western blotting. Real-time PCR test also demonstrated that substance P mRNA was decreased, while adrenomedullin and intercellular adhesion molecule mRNA was increased following AMD3100 treatment.<h4>Conclusion</h4>Our results suggest that central (spinal) CXCR4 is involved in the development and maintenance of PNP and the regulation of multiple spinal molecular events under pain condition, implicating that CXCR4 would potentially be a therapeutic target for chronic neuropathic pain.
format	article
author	Xin Luo Wai Lydia Tai Liting Sun Qiu Qiu Zhengyuan Xia Sookja Kim Chung Chi Wai Cheung
author_facet	Xin Luo Wai Lydia Tai Liting Sun Qiu Qiu Zhengyuan Xia Sookja Kim Chung Chi Wai Cheung
author_sort	Xin Luo
title	Central administration of C-X-C chemokine receptor type 4 antagonist alleviates the development and maintenance of peripheral neuropathic pain in mice.
title_short	Central administration of C-X-C chemokine receptor type 4 antagonist alleviates the development and maintenance of peripheral neuropathic pain in mice.
title_full	Central administration of C-X-C chemokine receptor type 4 antagonist alleviates the development and maintenance of peripheral neuropathic pain in mice.
title_fullStr	Central administration of C-X-C chemokine receptor type 4 antagonist alleviates the development and maintenance of peripheral neuropathic pain in mice.
title_full_unstemmed	Central administration of C-X-C chemokine receptor type 4 antagonist alleviates the development and maintenance of peripheral neuropathic pain in mice.
title_sort	central administration of c-x-c chemokine receptor type 4 antagonist alleviates the development and maintenance of peripheral neuropathic pain in mice.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/baece4fdcba340a095d59d3f96ca0ab4
work_keys_str_mv	AT xinluo centraladministrationofcxcchemokinereceptortype4antagonistalleviatesthedevelopmentandmaintenanceofperipheralneuropathicpaininmice AT wailydiatai centraladministrationofcxcchemokinereceptortype4antagonistalleviatesthedevelopmentandmaintenanceofperipheralneuropathicpaininmice AT litingsun centraladministrationofcxcchemokinereceptortype4antagonistalleviatesthedevelopmentandmaintenanceofperipheralneuropathicpaininmice AT qiuqiu centraladministrationofcxcchemokinereceptortype4antagonistalleviatesthedevelopmentandmaintenanceofperipheralneuropathicpaininmice AT zhengyuanxia centraladministrationofcxcchemokinereceptortype4antagonistalleviatesthedevelopmentandmaintenanceofperipheralneuropathicpaininmice AT sookjakimchung centraladministrationofcxcchemokinereceptortype4antagonistalleviatesthedevelopmentandmaintenanceofperipheralneuropathicpaininmice AT chiwaicheung centraladministrationofcxcchemokinereceptortype4antagonistalleviatesthedevelopmentandmaintenanceofperipheralneuropathicpaininmice
_version_	1718414243102982144

Central administration of C-X-C chemokine receptor type 4 antagonist alleviates the development and maintenance of peripheral neuropathic pain in mice.

Ejemplares similares